The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

iwNHL 2023 | Evolving treatment landscape of MCL

Name: Evolving treatment landscape of MCL
Uploaded: 2023-10-17T00:00:00Z
Description: In this discussion, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Marek Trněný, MD, PhD, Charles University, Prague, Czech Republic, John Kuruvilla, MD, Princess Margaret Cancer Centre, Toronto, Canada, and Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, discuss the evolving treatment landscape of MCL, commenting on the impact of novel therapies in this disease.

John Kuruvilla, Marek Trněný, Stephen Ansell and Yucai Wang • 17 Oct 2023

iwNHL 2023

Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma BTK inhibitors CAR-T Ibrutinib Rituximab

TRIANGLE

In this discussion, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Marek Trněný, MD, PhD, Charles University, Prague, Czech Republic, John Kuruvilla, MD, Princess Margaret Cancer Centre, Toronto, Canada, and Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, discuss the evolving treatment landscape of MCL, commenting on the impact of novel therapies in this disease.